Phase II Trial of Erlotinib Plus Bevacizumab for Patients with Advanced Non-Small-Cell Lung Cancer Who harboring EGFR mutation.
- Conditions
- on Small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000005934
- Lead Sponsor
- Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Not provided
1) Pulmonary disorder(idiopathic pulmonary fibrosis,interstitial lung disease, pneumoconiosis, active radiation pneumonia, etc.). 2) EGFR-TKI resistance EGFR mutation (T790M) 3) Prior treatment with Gefitinib or Erlotinib. 4) Unavailability of oral administration. 5) History of hemoptysis. 6) Tumor invasion to major vessels 7) History of gastrointestinal perforation or diverticulitis or fistula 8) History of cardiac infarction or brain infarction. 9) Scheduled operation. 10) Uncontrollable hypertension. 11) Symptomatic brain metastasis. 12) A history of allergic reaction for the treatment drugs. 13) Uncontrollable pleural effusion or peritoneal effusion. 14) History of severe comorbidity disease. 15) History of active double cancer. 16) Unstable psychic disorder. 17) Pregnant patients. 18) Decision of ineligibility by a physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free Survival
- Secondary Outcome Measures
Name Time Method Response Rate, Disease Control Rate, Overall Survival, Safety